CD276 and breast carcinoma: To assess the B7-H3-specific cytotoxicity of dHBD, including ITC-6102RO, human lung cancer H23 cells and human breast cancer JIMT-1 cells were treated with ITC-6102RO, and their viabilities were evaluated.